Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53

Fig. 4

HDACs/mTOR inhibitor 1 synergize with pyrotinib and induces PDAC cells to apoptosis in vitro. A Dose–response matrix of inhibition rates of AsPC-1 and CFPAC-1 treated with dosages of pyrotinib (0, 0.1, 0.2, 0.4, 0.8, 1.6 μM) or HDACs/mTOR inhibitor 1 (0, 0.1, 0.2, 0.4, 0.8, 1.6 μM); most of the region in the right block showing Bliss synergy score surpass 10, meaning synergistic effect. B Representative pictures of cells underwent apoptosis or not during 72 h; AsPC-1 and CFPAC-1 were treated with DMSO, 0.8 μM of pyrotinib, 0.2 μM(AsPC-1) or 0.4 μM(CFPAC-1) of HDACs/mTOR inhibitor 1 or the combination, arrows showing morphology of apoptosis initiated within 24 h. C Proliferation curves of AsPC-1 and CFPAC-1 treated with monotherapy and combination for 120 h. Cell numbers were indirectly indicated using confluence. D Colony formation assay of AsPC-1 and CFPAC-1 treated with monotherapy and combination for 7 days. E Apoptosis analysis in AsPC-1 and CFPAC-1; cells treated with pyrotinib, HDACs/mTOR inhibitor 1 or combinations were stained with Annexin V/PI. F Western blot of cells treated with pyrotinib, HDACs/mTOR inhibitor 1 or combinations with PARP and cleavage PARP. Data are represented as mean ± SD. Statistical significance was assessed using a Student t test. *P < 0.05, **P < 0.01, ***P < 0.001. ns not significant

Back to article page